Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus
Maintaining weight loss after GLP-1 treatment is possible, but it should be planned before regain starts
It also replenishes essential nutrients that are needed in the body for further biological actions
The REST trial, registered as NCT07294950, will randomise people living with obesity and without preexisting cardiovascular disease all currently receiving semaglutide for weight management, all having achieved at least 10% prior weight reduction with no further loss over the past 12 weeks to either a gradual dose reduction over 16 weeks or immediate discontinuation [6]
US$ 29.02
US$ 20.56
US$ 29.80
US$ 29.11
US$ 27.59
US$ 22.14
